Quest Diagnostics Incorporated DGX NYSE

Quest Diagnostics Incorporated (DGX) has shown moderate revenue growth over the past 3 years, expanding from $9.9B to $11.0B (average +4%/yr). Net income reached $992M, reflecting modest earnings improvement at +2.1%/yr on average. The net profit margin is 9%, which is moderate. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 31.9% (moderate), with a -2.8pp trend over the period. With a $21B market cap and MOAT composite score of 61/100, the company has a moderate competitive position.

Criteria proven by this page:

• GROWTH (45/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 30-year history, the company was profitable in 27 of 30 years — an excellent long-term track record
• INCOME (45/100, Partial) — the company is profitable but margin is below 15%
• MOAT (61/100, Partial) — some competitive advantages are present but not dominant

Overall SharesGrow Score: 55/100 with 1/7 criteria passed.